Browsing Tag
Vopimetostat
4 posts
Did Tango Therapeutics Inc. just turn one cancer data shock into a $600m runway?
Find out how Tango Therapeutics Inc.'s $600 million offering could reshape TNGX sentiment, dilution risk, and its oncology runway.
June 10, 2026
Tango Therapeutics (TNGX) soars on striking pancreatic cancer data, then moves to cash in
Tango Therapeutics soared 50%+ on early pancreatic cancer data, a 92% response rate for vopimetostat plus daraxonrasib, then filed a $500M offering to cash in.
June 9, 2026
Erasca (NASDAQ: ERAS) climbs into ASCO 2026 as pan-RAS thesis gets second wind
Erasca lost half its value on an IP challenge and a trial death. Now ASCO 2026 looms, Merck is on board, and traders are positioning before the verdict.
May 27, 2026
Tango Therapeutics (NASDAQ: TNGX) jumps 11% into May 11 earnings and pivotal pancreatic cancer data
Tango Therapeutics is up 22-fold from $1.04 in twelve months. The May 11 earnings print decides whether vopimetostat justifies the run or breaks it.
May 5, 2026